NEW YORK (GenomeWeb News) – Roche today announced an agreement to acquire MTM Laboratories for up to €190 million ($269 million) in a deal that expands Roche's capabilities in cervical cancer testing.
Roche will pay an upfront fee of €130 million and up to €60 million in milestone payments. Upon completion of the acquisition, MTM will become part of Roche's Tissue Diagnostics business unit. Roche said it expects to close the deal in the coming weeks.